Deans' stroke musings: FDA approves transdermal patch to treat Alzheimer’s-related dementia

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, March 16, 2022

FDA approves transdermal patch to treat Alzheimer’s-related dementia

Is this just for Alzheimers or can it be used for any dementia/cognitive decline? WHOM in the stroke world is going to answer that extremely simple question? Ok, I looked back at my earlier posts and you don't want to use donepezil for mild cognitive impairment.

When people experience memory loss that looks a little like Alzheimer's but isn't, doctors diagnose it as "Mild Cognitive Impairment (MCI)". Some prescribe the Alzheimer's drug donepezil (Aricept®). New research shows why it should not be prescribed for people with mild cognitive impairment (MCI) without a genetic test.
UCLA School of Nursing researchers discovered that for people who carry a specific genetic variation — the K-variant of butyrylcholinesterase, or BChE-K — donezpezil could accelerate cognitive decline.

FDA approves transdermal patch to treat Alzheimer’s-related dementia

Biopharmaceutical company Corium announced that the FDA has approved Adlarity to treat patients with mild, moderate or severe dementia associated with Alzheimer’s disease, according to a press release.

The FDA approved once-weekly use of Adlarity (donepezil, Corium) in 5 mg/day or 10 mg/day formulations. The transdermal patch, which can be placed by a patient or caregiver on a patient's back, thigh or buttocks, delivers a consistent dose of donepezil through the skin, resulting in a low likelihood of adverse gastrointestinal side effects associated with oral donepezil. Patients may be switched from 5 mg/day or 10 mg/day oral donepezil directly to Adlarity by their prescriber.

“The FDA approval of Adlarity brings to market a new and innovative way to deliver consistently a well-tolerated form of donepezil, the most widely used medicine for patients with Alzheimer's disease,” Perry J. Sternberg, president and CEO of Corium, said in the release. “We feel truly privileged to have the opportunity to potentially help millions of people in the U.S. living with Alzheimer's disease, their loved ones and their caregivers with a new option that can address some of the current challenges in treatment and care.”

FDA approves asenapine transdermal patch for schizophrenia
FDA gives breakthrough designation to assay for early Alzheimer’s

Adlarity is expected to be available in early fall 2022.